Investment Thesis
Alto Neuroscience is a pre-revenue pharmaceutical company with severe operational losses and negative free cash flow, indicating the business is in early clinical development with no commercial products generating revenue. Despite strong liquidity and balance sheet strength, the company is burning substantial cash (-$51.8M operating CF) with only 6.7 years of cash runway at current burn rates, creating significant going concern risk before reaching profitability.
ANRO Strengths
- Strong liquidity position with $176.5M cash equivalents and 15.69x current ratio
- Minimal debt burden with 0.11x debt-to-equity ratio providing financial flexibility
- Net loss improved 2.9% YoY indicating some operational progress
ANRO Risks
- Pre-revenue stage with no commercial products; entirely dependent on clinical trial success and regulatory approval
- Substantial cash burn of $51.8M annually from operations will exhaust capital within ~6-7 years without revenue generation
- Negative returns on equity (-41.8%) and assets (-34.2%) demonstrate value destruction; typical for biotech but reflects execution risk
- Diluted EPS of -$2.19 indicates significant shareholder dilution through financing activities common in pre-revenue biotech
Key Metrics to Watch
- Monthly cash burn rate and cash runway extension timeline
- Clinical trial progress and regulatory pathway developments for lead candidates
- Quarterly operating cash flow trends toward profitability or stabilization
- Capital raise activity and dilution impact on equity
- Revenue generation timeline and commercial milestone achievements
ANRO Financial Metrics
ANRO Profitability Ratios
ANRO Balance Sheet & Liquidity
ANRO 5-Year Financial Trend
5-Year Trend Summary: Alto Neuroscience, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.50 indicates the company is currently unprofitable.
ANRO Growth Metrics (YoY)
ANRO Capital Allocation
ANRO SEC Filings
Access official SEC EDGAR filings for Alto Neuroscience, Inc. (CIK: 0001999480)